Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Cash flows from operating activities:    
Net loss $ (11,818,652) $ (14,243,084)
Stock option compensation to employees and directors 3,560,883 5,717,651
Stock options and warrants issued to consultants 198,421 318,139
Restricted stock award compensation to employee pursuant to stock incentive plan 1,954,441 2,859,824
Common stock issued to consultants 15,002
Amortization of patents 418,750 325,296
Depreciation of property and equipment 47,558 18,435
Impairment in carrying amount of patent assets 418,750 582,979
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee 64,656
Change in operating assets and liabilities:    
Receivables 271,700 (258,991)
Prepaid expenses and other current assets (9,481) (48,925)
Accounts payable 3,805 101,688
Accrued expenses 212,399 273,930
Net cash used in operating activities (4,741,426) (4,273,400)
Cash flows from investing activities:    
Disbursements to acquire short-term investments in certificates of deposit (3,850,000) (4,250,000)
Proceeds from maturities of short-term investments in certificates of deposit 3,500,000 5,750,000
Purchase of property and equipment (175,457) (38,404)
Net cash (used in) provided by investing activities (525,457) 1,461,596
Cash flows from financing activities:    
Proceeds from sale of common stock in at-the-market offering 5,527,428 2,470,182
Proceeds from sale of common stock pursuant to employee stock purchase plan 39,086
Proceeds from settlement of shareholder derivative complaint 14,034
Proceeds from exercise of stock options and warrants 122,070 58,138
Net cash provided by financing activities 5,702,618 2,528,320
Net increase (decrease) in cash and cash equivalents 435,735 (283,484)
Cash and cash equivalents at beginning of year 3,055,890 3,339,374
Cash and cash equivalents at end of year 3,491,625 3,055,890
Supplemental cash flow information:    
Cash proceeds from interest income 55,729 12,684
Supplemental disclosure of non-cash investing activity:    
Disposal of fully depreciated property and equipment (6,343)
Supplemental disclosure of non-cash financing activity:    
Note receivable issued for settlement of shareholder derivative complaint $ 31,236